The News Feed

AMD

Retinal Sensitivity Varies Across Macula in Early, Intermediate AMD

A recent study correlated microperimetry and contrast sensitivity findings with disease stage, suggesting potential news ways to tracking progression.
July 26, 2024

Study Highlights Prognostic Value of Choriocapillaris Alterations in AMD Progression

This offers a potential biomarker for risk stratification and monitoring that could lead to more targeted clinical interventions, researchers say.
July 23, 2024

Eyecare Appointments, Services Less Common in Those with Dementia

Patients with coexisting glaucoma or AMD received less care on average than their counterparts without the neurodegenerative condition in a recent study.
July 22, 2024

JAK Inhibitors May Reduce Risk of AMD in Patients with Autoimmune Diseases, Study Finds

The effect was seen in patients using these agents to treat systemic inflammation. More work needs to be done before it could be considered a primary therapy for retinal conditions, however.
July 16, 2024

Landolt C Testing Reveals Lower Pursuit Gains for Those with AMD

This impairment likely further compromises their dynamic VA and thus ability to view moving targets.
June 27, 2024

Standing Test Reveals Impaired Hemodynamic Effects in AMD

The result of the first 20 seconds could be associated with the pathophysiology of the disease's progression.
June 20, 2024

Melatonin Shown to Decrease Risk of AMD Development and Progression

Researchers acknowledged that lifestyle changes may have also contributed, but nevertheless speculated that the drug may reduce oxidative stress and subsequent VEGF overexpression.
June 10, 2024

Personalized Wet AMD Management with At-Home OCT Possible

While from a small study of 27 eyes, recent findings showed an almost 50% reduction in treatment burden while maintaining stable visual acuity.
May 28, 2024

Low-dose Aspirin Not Effective in Preventing AMD

The regimen also wasn’t helpful in slowing or preventing progression of the disease.
May 24, 2024

High-dose Aflibercept Pushes Dosing Interval to Five Months

Nearly half of subjects went 20 weeks or longer between injections with the 8mg formulation. The regimen also maintained BCVA gains out to 96 weeks.
May 13, 2024